Compare Moderna, Inc. (MRNA) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Value Index Fund ETF — how do they compare? Moderna, Inc. trades at $224.78 (market cap $78.65B), while Vanguard Value Index Fund ETF trades at $220.6 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 3.3× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Vanguard Value Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| MRNA | VTV | |
|---|---|---|
Market Cap | $78.65B | $262.40B |
Volume | 37,373,437 | 3,293,281 |
Sector | Health | — |
52-Week High | $203.46 | $227.51 |
52-Week Low | $22.36 | $182.86 |
Typical Hold Time | 59 Days | 142 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
VTV trades at $220.55, up 1.07% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital Management and Blue Edge Capital. Recent news highlights value stocks outperforming growth in 2026, with VTV's 2.3% yield and low 0.03% fee attracting income-focused investors amid market rotation from tech.
The outlook remains mixed—technical indicators suggest near-term pressure, but strong institutional interest and value stock momentum support long-term stability. Key risks include underperformance versus broad market indices and sensitivity to interest rate changes. The dividend yield provides income cushion, yet investors should weigh VTV's value tilt against broader market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
